The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)

被引：0
|
作者：
Kamiyama, H. [1 ]
Yoshida, Y. [2 ]
Yoshida, H. [3 ]
Kosugi, C. [4 ]
Ishibashi, K. [5 ]
Ihara, K. [6 ]
Takahashi, M. [1 ]
Kuramochi, H. [7 ]
Fukazawa, A. [8 ]
Sonoda, H. [9 ]
Yoshimatsu, K. [10 ]
Matsuda, A. [11 ]
Yamaguchi, S. [6 ]
Ishida, H. [5 ]
Hasegawa, S. [2 ]
Yamada, T. [3 ]
Sakamoto, K. [1 ]
Koda, K. [4 ]
机构：
[1] Juntendo Univ, Sch Med, Coloproctol Surg, Tokyo, Japan
[2] Fukuoka Univ, Sch Med, Gastroenterol Surg, Fukuoka, Fukuoka, Japan
[3] Nippon Med Sch, Gastroenterol Surg, Tokyo, Japan
[4] Teikyo Univ, Chiba Med Ctr, Surg, Ichihara, Chiba, Japan
[5] Saitama Med Univ, Digest Tract & Gen Surg, Saitama, Japan
[6] Dokkyo Med Univ, Surg Oncol, Mibu, Tochigi, Japan
[7] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Chemotherapy, Yachiyo, Japan
[8] Iwata City Hosp, Surg, Shizuoka, Japan
[9] Shiga Med Univ, Gastroenterol Surg, Shiga, Japan
[10] Tokyo Womens Med Univ, Surg, Tokyo, Japan
[11] Chiba Hokusoh Hosp, Nippon Med Sch, Surg, Inzai, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
469P
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [1] The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
    Kosugi, Chihiro
    Kamiyama, Hirohiko
    Yoshida, Yoichiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Fukazawa, Atsuko
    Matsuda, Akihisa
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Narushima, Kazuo
    Shuto, Kiyohiko
    Sakamoto, Kazuhiro
    Koda, Keiji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [3] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoichiro Yoshida
    Takeshi Yamada
    Hirohiko Kamiyama
    Chihiro Kosugi
    Keiichiro Ishibashi
    Hiroshi Yoshida
    Hideyuki Ishida
    Satoru Yamaguchi
    Hidekazu Kuramochi
    Atsuko Fukazawa
    Hiromichi Sonoda
    Kazuhiko Yoshimatsu
    Akihisa Matsuda
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Koda
    International Journal of Clinical Oncology, 2021, 26 : 111 - 117
  • [4] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [5] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    CANCER SCIENCE, 2018, 109 : 601 - 601
  • [6] The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study)
    Matsuda, Akihisa
    Yoshida, Yoichiro
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Sakamoto, Kazuhiro
    Koda, Keiji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] Biweekly TAS-102 and bevacizumab as a third-line chemotherapy for metastatic colorectal cancer: A phase II multicenter clinical trial (TAS-CC4 study)
    Yoshida, Y.
    Yamada, T.
    Matsuoka, H.
    Hirata, K.
    Kuramochi, H.
    Kosugi, C.
    Takahashi, M.
    Fukazawa, A.
    Sonoda, H.
    Matsuda, A.
    Watanabe, T.
    Koizumi, M.
    Aisu, N.
    Hasegawa, S.
    Yoshida, H.
    Sakamoto, K.
    Ishida, H.
    Koda, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 235 - 235
  • [8] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
    Liu, Cheng-Jiang
    Hu, Ting
    Shao, Ping
    Chu, Wu-Yang
    Cao, Yu
    Zhang, Feng
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
  • [9] TAS-102 plus bevacizumab in metastatic colorectal cancer
    Colloca, Giuseppe A.
    Venturino, Antonella
    LANCET ONCOLOGY, 2020, 21 (05): : E226 - E226
  • [10] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
12345